Are Daily Contacts Actually Better Than Monthlies?
You don't need 20/20 vision to clearly see the benefits of daily contacts, eye doctors agree. Compared to monthlies, daily lenses 'have a pretty big advantage,' says Dr. William McLaughlin, an optometrist at The Ohio State University Wexner Medical Center. 'They're more comfortable, more convenient, and you'll have better eye health if you're using a fresh lens every day. They're absolutely the way to go.'
Here's a look at why daily lenses beat out monthlies—plus how to put the higher price tag into perspective.
They counteract bad habits
Daily lenses are an 'easy yes' for people whose contact hygiene could use a tune-up, says Dr. Neal Guymon, an optometrist in Idaho known as Dr. EyeGuy online. That includes those who sleep in their lenses (which deprives oxygen from the eyes, just like 'sleeping with a paper bag over your head,' he says), don't clean their cases regularly, slack on subbing in new contact solution, and forget to switch into a new pair every month.
Contact overuse—wearing lenses for more days than you should—can lead to inflammation on the eyeballs or eyelids, including giant papillary conjunctivitis, which is essentially an allergic reaction to wearing contacts for too long. 'It can be super irritating and hard to get rid of,' Guymon says. Sometimes, overuse can cause lenses to be 'clogged up with debris, so they lose the ability to transfer oxygen through the contact,' he adds, which leads to corneal neovascularization, or blood vessels that burrow into the cornea.
Read More: Battling Dry Eyes? Here's What Actually Helps
How you take care of your monthly lenses when they're not in your eyes matters, too. Contact cases harbor bacteria and biofilm (the sticky, slimy film that accumulates on your eyelids), so you should wash them every day, after you pop your lenses in. It's also a good idea to replace the case once a month, Guymon says, perhaps getting into the habit of doing so when you switch into a new pair of lenses. You should also replace the disinfectant solution in your case every day.
'When people come into my practice because they have an eye infection or an eye problem that's related to contact lenses, 99 times out of 100, it's someone who's either been sleeping in contacts or wearing the same lenses for three months,' Guymon says. 'Dailies are better, but they're not necessarily better because they're the better contact (which they are). It's more because people treat them the way they should be treated.'
They have superior construction
When daily lenses were introduced in the 1990s, ophthalmologists worried that people would wear them for more than just one day—that they'd buy a 90-pack and then never see their eye doctor again, stretching the lenses out far longer than they should. But those concerns didn't come to fruition. Daily lenses are so comfortable that people tend to quickly adapt to their new routine: Wake up, pop in a fresh set, go about the day, and then take them out and toss them in the trash, no solution or contact case required.
'It's a mindset,' says Dr. Christine Sindt, a clinical professor of ophthalmology and visual sciences at the University of Iowa's Carver College of Medicine. 'If you try to wear a daily disposable the second day, you will physically go, 'Oh, I don't feel as good.' People notice it, because it feels so good that first day. It turns out that when people wear dailies, it becomes who they are—it's their pattern of behavior.'
Read More: 10 Symptoms ER Doctors Say to Never Ignore
In part, that's because daily lenses are constructed differently than monthlies. They're thinner, which means they're less likely to create small corneal abrasions, or scratches on the surface of the eye. Plus, they're made out of different plastics and have different surface coatings that allow them to be more biocompatible, which means they don't harm any living tissue. (Monthlies, on the other hand, can, especially if you wear them for longer than their intended lifespan.) Some dailies, for example, are coated with phospholipid, which is what cell membranes are made of. 'For patients who have dry eyes, I'll put this lens on them, and it'll feel like a cozy blanket on the surface of their eye,' Sindt says. 'These lenses aren't only more comfortable [than monthlies]—in many cases, they're more comfortable than the bare eye.'
They prevent grimy buildup
When you wear the same contacts every day, they attract all kinds of proteins, lipids, and enzymes that are found in the tear film that keeps your eyes lubricated. 'When you have a foreign body in the eye, every time you blink, the body's mechanism is to try to protect itself,' which means it will secrete tears, says Dr. Shahzad Mian, a professor of ophthalmology and visual sciences at University of Michigan. 'The more irritated the eyes are, the more proteins there are in your tear film—and those deposits then stick to the contact lens and cause even further irritation. It's a bad cycle some patients get stuck in.'
If you're wearing daily lenses, on the other hand, you'll be tossing any buildup out at the end of the day—which means it won't have the chance to accumulate.
They protect against infection
Sindt is a 'huge fan of daily disposable contact lenses,' she says. 'And the reason is, I've been doing this a very long time, and I've seen a lot of eye infections. Wearing contact lenses is not benign.'
When people land in her exam room, they've often developed a painful bacterial, parasitic, or fungal eye infection stemming from poor contact hygiene or overuse. While some infections cause little more than irritation, others could lead to vision loss or require a corneal transplant. 'I see the patients who have had adverse events,' Sindt says. 'I hear the stories, and it's an everyday thing. It's kind of like playing Russian Roulette, people who don't take care of their contact lenses.'
You can generally get away with poor contact hygiene for a while, especially when you're young. Youth is an 'amazing protectant," Sindt says—young people have thicker tear films, as well as eyes that are less likely to become inflamed. But that doesn't last forever. 'If somebody goes along with their bad habits, at some point, they're going to get older, and they're going to end up with an infection,' she says. 'It catches up to everybody.'
Read More: What to Do About Your Red, Itchy Eyes
That's why even though dailies generally cost more than monthlies, eye experts say they're worth it. You'll save on contact solution and new cases, for one thing. Plus, 'what's the cost of an eye infection?' Sindt says. 'If you have a red eye and you have to take time off work—or if you hurt—what's the cost of pain? What's the cost of being annoyed? Those are all costs that people don't think of up front.'
Contact us at letters@time.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Missouri confirms case of rare brain-eating amoeba infection
A person in Missouri has been hospitalized after contracting a brain-eating amoeba, possibly after water skiing in the Lake of the Ozarks, state health officials said Wednesday. The patient, who was not identified, is being treated in an intensive care unit for an infection of the Naegleria fowleri amoeba, the Missouri Department of Health and Senior Services said. Public health officials are still investigating the source of the infection, but the Health Department said the patient became ill days after they were at the lake. There are two public beaches open to visitors at the Lake of the Ozarks State Park, according to the park's website. The Health Department did not specify which beach the patient had gone to. While the Naegleria fowleri organism is common in warm freshwater, the infection — called primary amebic meningoencephalitis, or PAM — is rare, health officials say. It occurs when water is forced up the nose and is able to cross into the brain, which can happen during recreational freshwater activities. Between 1962 and 2024, there have been 167 reported cases of PAM in the United States, the Missouri Department of Health and Senior Services said. Last month, 12-year-old Jaysen Carr died in South Carolina after getting infected. The South Carolina Department of Public Health said it was the first known case in the state since 2016. The family of Jaysen Carr later spoke publicly about their son's death, saying they "do not want this to happen to anyone else." To reduce the risk of infection, the Centers for Disease Control and Prevention suggests holding your nose or wearing a nose clip if you are jumping or diving into freshwater or keeping your head above water in hot springs. Signs of infection include nausea, vomiting, fever, a severe headache, stiff neck, seizures, altered mental state and hallucinations. You cannot get a Naegleria fowleri infection from swallowing contaminated water or from someone else who is infected. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Tropical Storm Erin expected to become a major hurricane Could Tropical Storm Erin become the first Atlantic hurricane of 2025? Solve the daily Crossword
Yahoo
26 minutes ago
- Yahoo
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the 'Company' or 'Opus Genetics'), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'We've made significant progress across our pipeline, with multiple clinical and regulatory milestones achieved this quarter,' said George Magrath, M.D., Chief Executive Officer, Opus Genetics. 'Receiving RMAT designation for our OPGx-LCA5 program underscores the strength of our clinical data and the urgent need for effective gene therapies to treat inherited retinal diseases. We are encouraged by the sustained functional vision improvements observed in adult patients in our clinical trial to date and the early signs of efficacy in the pediatric cohort. In parallel, our advancement of OPGx-BEST1 toward the clinic and the nomination of two additional development candidates in partnership with the Retinal Degeneration Fund and the Global RDH12 Alliance highlight the breadth of our IRD pipeline.' 'Beyond gene therapy, the positive readouts from our two Phase 3 Phentolamine trials represent a major step toward our goal of bringing a new treatment option to millions of patients living with vision challenges. With several upcoming key milestones, including new clinical data, a supplemental New Drug Application (sNDA) submission, and the launch of a pivotal study, we remain focused on execution to deliver transformative treatments to patients with significant unmet needs,' Dr. Magrath concluded. Pipeline Updates OPGx-LCA5 – Gene Therapy for Leber Congenital Amaurosis (LCA) The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5, for the treatment of Leber Congenital Amaurosis (LCA) due to genetic variations in the LCA5 gene, signifying the program's potential to address a serious condition and providing a pathway for accelerated development and review. Twelve-month clinical data from adult participants in the Phase 1/2 trial demonstrated sustained improvements in visual function, including visual acuity gains and improved mobility testing scores. This data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May. Initial pediatric data at one-month post-treatment showed vision improvement with no drug-related adverse events; three-month pediatric data is expected to be reported in Q3 2025. OPGx-BEST1 – Gene Therapy for BEST1-Related IRD Preclinical data presented at the American Ophthalmological Society (AOS) in May demonstrated restoration of the retinal pigment epithelium-photoreceptor interface in a canine model of BEST1 using AAV-mediated gene delivery. Investigational New Drug (IND) submission and Phase 1/2 trial initiation remain on track for the second half of 2025. OPGx-RDH12 and OPGx-MERTK – Advancing with Non-Dilutive Support Partnership with the Global RDH12 Alliance provides up to $1.6 million in non-dilutive funding to accelerate development of OPGx-RDH12 for Leber congenital amaurosis (RDH12-LCA). Non-dilutive funding up to $2 million received from the Retinal Degeneration Fund to advance OPGx-MERTK, targeting retinitis pigmentosa caused by MERTK mutations. Preclinical OPGx-MERTK data presented at the American Society of Gene & Cell Therapy (ASGCT) in May showed preservation of retinal function in animal models. Phentolamine Ophthalmic Solution 0.75% – Advancing Toward sNDA Submissions VEGA-3 Phase 3 trial met its primary and multiple secondary endpoints in presbyopia, with 27.2% of treated patients achieving a ≥15-letter gain in near visual acuity (vs. 11.5% on placebo, p<0.0001) and favorable participant reported outcomes and safety profile. LYNX-2 Phase 3 trial met its primary and multiple secondary endpoints in keratorefractive patients with night vision disturbances. Patients showed statistically significant gains in mesopic low contrast vision and improvements in night-driving related symptoms. sNDA submission for presbyopia indication planned for the second half of 2025. LYNX-3 Phase 3 trial expected to initiate enrollment in the second half of 2025 targeting reduced low light vision and nighttime visual disturbances. Additional Medical Meeting Presentations Virtual reality-guided functional testing to support meaningful clinical endpoints in IRD trials was presented at the Retinal Imaging Biomarkers Summit. Upcoming Expected Data Readouts and Program Advancements Report three-month pediatric data from OPGx-LCA5 Phase 1/2 trial in Q3 2025. Initiate enrollment in Phase 1/2 trial for OPGx-BEST1 in H2 2025. Submit Phentolamine sNDA for presbyopia in H2 2025. Initiate enrollment in Phentolamine LYNX-3 Phase 3 trial in H2 2025. Financial Results for the Second Quarter Ended June 30, 2025 Cash Position: As of June 30, 2025, Opus Genetics had cash and cash equivalents of $32.4 million. Based on current operating plans, the Company expects its existing cash resources will fund operations into the second half of 2026. Revenue: License and collaboration revenue totaled $2.9 million for the second quarter of 2025, compared to $1.1 million in the same period in 2024. Revenue in both periods was driven by the Company's collaboration with Viatris, Inc., primarily from reimbursement of R&D services. General and Administrative (G&A) Expenses: G&A expenses were $5.8 million for the second quarter of 2025, compared to $3.4 million for the same period in 2024. The increase was mainly due to higher costs associated with legal and patent-related expenses, payroll, and business development activities. G&A expenses included $0.6 million and $0.5 million in stock-based compensation in the second quarters of 2025 and 2024, respectively. Research and Development (R&D) Expenses: R&D expenses were $6.0 million for the second quarter of 2025, compared to $6.1 million in the prior-year period. The slight decrease was primarily due to lower manufacturing and consulting costs, partially offset by increased clinical trial, toxicology, and payroll-related expenses. R&D expenses related to Phentolamine Ophthalmic Solution 0.75% were fully reimbursed under the Viatris License Agreement. Stock-based compensation within R&D expenses was $0.3 million in both periods. Net Loss: Net loss for the second quarter of 2025 was $7.4 million, or $(0.12) per basic and diluted share, compared to a net loss of $7.8 million, or $(0.30) per basic and diluted share, for the second quarter of 2024. SEC Filing: Additional details on the Company's financial results will be available in its Quarterly Report on Form 10-Q for the period ended June 30, 2025, to be filed with the U.S. Securities and Exchange Commission (SEC). About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway, the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading 'Risk Factors' included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Contacts: InvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@ MediaKimberly HaKKH Opus Genetics, Consolidated Balance Sheets(in thousands, except share amounts and par value) As of June 30, December 31, 2025 2024 Assets (Unaudited) Current assets: Cash and cash equivalents $ 32,429 $ 30,321 Accounts receivable 3,399 3,563 Contract assets and unbilled receivables 1,178 2,209 Prepaids and other current assets 1,433 515 Short-term investments — 2 Total current assets 38,439 36,610 Property and equipment, net 226 252 Total assets $ 38,665 $ 36,862 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,465 $ 3,148 Accrued expenses and other liabilities 6,927 8,147 Warrant liabilities 11,800 — Total current liabilities 20,192 11,295 Long-term funding agreement, related party 1,000 — Total liabilities 21,192 11,295 Commitments and contingencies Series A preferred stock, par value $0.0001; 14,146 shares were designated as of June 30, 2025 and December 31, 2024; zero and 14,145.374 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. — 18,843 Stockholders' equity: Preferred stock, par value $0.0001; 9,985,854 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024. — — Common stock, par value $0.0001; 125,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 59,908,055 and 31,574,657 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 6 3 Additional paid-in capital 172,079 145,719 Accumulated deficit (154,612 ) (138,998 ) Total stockholders' equity 17,473 6,724 Total liabilities, series A preferred stock and stockholders' equity $ 38,665 $ 36,862 Opus Genetics, Consolidated Statements of Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 License and collaborations revenue $ 2,882 $ 1,112 $ 7,252 $ 2,823 Operating expenses: General and administrative 5,766 3,354 12,112 8,024 Research and development 6,022 6,086 13,975 10,835 Total operating expenses 11,788 9,440 26,087 18,859 Loss from operations (8,906 ) (8,328 ) (18,835 ) (16,036 ) Fair value change in warrant and other derivative liabilities 917 — 3,722 — Financing costs 35 — (1,337 ) — Other income, net 534 563 836 1,165 Loss before income taxes (7,420 ) (7,765 ) (15,614 ) (14,871 ) Benefit (provision) for income taxes — — — — Net loss (7,420 ) (7,765 ) (15,614 ) (14,871 ) Other comprehensive loss, net of tax — — Comprehensive loss $ (7,420 ) $ (7,765 ) $ (15,614 ) $ (14,871 ) Net loss per share: Basic and diluted $ (0.12 ) $ (0.30 ) $ (0.32 ) $ (0.59 ) Number of shares used in per share calculations: Basic and diluted 63,376,392 25,827,265 48,712,124 25,175,596 Source: Opus Genetics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update. 'The compelling results we are generating in both CSU and CIndU continue to reinforce our belief that briquilimab has the potential to be a highly differentiated therapy in mast cell-driven diseases,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'We continue to generate strong data, with briquilimab driving complete responses in 89% of patients across the 240 mg and 360 mg single-dose cohorts in the BEACON study in CSU, 73% of CSU patients at 12 weeks in the open-label extension dosed at 180mg Q8W, and 92% of CIndU patients in the 180mg SPOTLIGHT cohort. With the favorable safety and tolerability profile we continue to observe, we believe briquilimab has the potential to be an important treatment option in chronic urticarias, and we remain well-positioned to deliver multiple catalysts over the coming quarters, which we believe can drive meaningful benefits for patients and long-term value for stockholders.' 'Our investigation into the 240mg Q8W and the 240mg/180mg Q8W cohorts of the BEACON study, which did not demonstrate the rapid onset and deep symptom control at levels we have observed in previous cohorts at varying dose levels, remains ongoing,' said Daniel Adelman, M.D., Interim Chief Medical Officer of Jasper. 'We are pursuing a number of avenues of investigation and expect to provide an update on the status of the investigation later this year. Meanwhile, the lack of any observed dose-limiting safety signals in these two cohorts enables us to also proceed with redosing those patients with drug product from a different lot, as well as enrolling an additional 10-12 new patients across those cohorts. We plan to report data from both the new patients added and the redosed patients in late 2025.' Highlights for Second Quarter 2025 and Recent Weeks Presented updated data from the BEACON Phase 1b/2a of subcutaneous briquilimab in adult participants with CSU, as well as from CSU patients in the related open-label extension study, both of which demonstrated robust efficacy: 89% (8 of 9) of participants in the 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0) following a single dose, with 7 of those patients achieving an initial clinical response by week 2. 73% (8 of 11) patients in the open-label extension study at 180 mg Q8W maintained a complete response at 12 weeks, and 82% of patients (9 of 11) demonstrated well-controlled disease at 12 weeks. Data from an additional 10-12 new patients being enrolled across the 240mg Q8W and the 240mg/180mg Q8W BEACON cohorts as well as additional data from the open-label extension study are anticipated later this year. Briquilimab continued to be well-tolerated with no dose limiting toxicities observed, and any safety observations potentially related to KIT blockade were infrequent and generally limited to low grade events, none of which resulted in discontinuations or dose delays and the majority of which resolved during repeat dosing. Commenced an investigation to identify the root cause of an atypical absence of UAS7 reduction in 11 of the 13 patients enrolled in the 240mg Q8W and 240mg/180mg Q8W cohorts of the BEACON study. Among other factors being examined, Jasper is assessing potential product lot variability in one lot of drug product first introduced into the BEACON study in those two cohorts, as all 10 patients dosed with drug supply from that lot failed to show reductions in their reported UAS7 scores. Jasper expects to complete the investigation in the second half of 2025, and in the near-term has provided new clinical drug supply from a different lot for ongoing dosing of existing patients, and is enrolling an additional 10-12 new patients in aggregate across those two cohorts. Jasper expects that the additional data on these cohorts, expected to be reported in late 2025, should be adequate to complete dose selection for the planned Phase 2b CSU study, which is now expected to commence mid-2026. Presented data from the 180mg cohort in the SPOTLIGHT study demonstrating 92% (11 of 12) complete response rate, 100% (12 of 12) clinical response, no serious or grade or higher adverse events, and a rapid onset of action with responses observed as early as one week-post treatment. Implemented a corporate restructuring, including a workforce reduction of approximately 50%, to focus resources on its urticaria programs and preserve capital. As part of the reorganization, Dr. Edwin Tucker stepped down as Chief Medical Officer effective August 1, 2025. He was succeeded in an interim capacity by Dr. Adelman, a member of Jasper's scientific advisory board and an industry veteran with a strong track record of advancing therapies for allergy and immunology indications. Halted its non-mast cell focused clinical and preclinical programs, including ongoing investigator sponsored trials and the SCID clinical program, to concentrate fully on briquilimab development in mast-cell driven diseases such as CSU and CIndU. Jasper also halted enrollment in the ETESIAN study in asthma and expects to report data from that study, as well as determine next steps in asthma, once the investigation into the anomalous BEACON cohorts is completed, which is expected to be in the second half of 2025. Second Quarter Fiscal 2025 Financial Results Cash and cash equivalents as of June 30, 2025, totaled $39.5 million. Research and development expense for the three months ended June 30, 2025, was $21.2 million. General and administrative expense for the three months ended June 30, 2025, was $5.9 million. Jasper reported a net loss of $26.7 million, or basic and diluted net loss per share attributable to common stockholders of $1.74 for the three months ended June 30, 2025. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU, and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in both CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU and CIndU, its potential to be a highly differentiated therapy in mast cell-driven diseases, its potential to be an important treatment option in chronic urticarias; Jasper's ability to deliver multiple catalysts over the coming quarters, and the possibility such catalysts may drive meaningful benefits for patients and long term value for stockholders; Jasper's focus of its resources on the development of briquilimab in mast-cell driven diseases such as CSU and CIndU, including halting its other clinical and preclinical programs; the expected timing of announcing additional data from the BEACON and ETESIAN studies; the expected timing for initiating the planned Phase 2b CSU study; and the expected timing for completing the investigation regarding an atypical lack of UAS7 reduction in certain cohorts and for providing an update on such investigation. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper's investigation into the drug product lot may be inconclusive or may not lead to the anticipated conclusion; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Molly Devlin (media) Real Chemistry 443-416-6675 mdevlin@ JASPER THERAPEUTICS, CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except share and per share data)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses Research and development(1) $ 21,196 $ 11,296 $ 37,353 $ 21,594 General and administrative(1) 5,880 4,697 11,525 9,471 Total operating expenses 27,076 15,993 48,878 31,065 Loss from operations (27,076 ) (15,993 ) (48,878 ) (31,065 ) Interest income 437 1,450 1,061 2,836 Other expense, net (84 ) (40 ) (147 ) (82 ) Total other income, net 353 1,410 914 2,754 Net loss and comprehensive loss $ (26,723 ) $ (14,583 ) $ (47,964 ) $ (28,311 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.74 ) $ (0.97 ) $ (3.16 ) $ (2.00 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,333,962 14,986,367 15,178,904 14,160,634 (1) Amounts include non-cash stock based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Research and development $ 1,274 $ 1,009 $ 2,514 $ 1,829 General and administrative 543 473 1,114 822 Total $ 1,817 $ 1,482 $ 3,628 $ 2,651 JASPER THERAPEUTICS, CONSOLIDATED BALANCE SHEETS Assets June 30,2025 December 31,2024 Current assets: Cash and cash equivalents $ 39,510 $ 71,637 Prepaid expenses and other current assets 3,456 4,174 Total current assets 42,966 75,811 Property and equipment, net 1,331 1,875 Operating lease right-of-use assets 1,560 976 Restricted cash 417 417 Other non-current assets 192 820 Total assets $ 46,466 $ 79,899 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 8,034 $ 4,027 Current portion of operating lease liabilities 1,954 1,089 Accrued expenses and other current liabilities 10,512 10,121 Total current liabilities 20,500 15,237 Non-current portion of operating lease liabilities 201 724 Other non-current liabilities 2,264 2,264 Total liabilities 22,965 18,225 Commitments and contingencies — — Stockholders' equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 312,332 302,541 Accumulated deficit (288,833 ) (240,869 ) Total stockholders' equity 23,501 61,674 Total liabilities and stockholders' equity $ 46,466 $ 79,899 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data